We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Positron Emission Mammography Detects Smaller Tumors Than MRI

By MedImaging staff writers
Posted on 03 Jul 2008
In a recent independent study, a positron emission mammography (PEM) system was shown to be more accurate than magnetic resonance imaging (MRI) in detecting very small tumors.

Naviscan PET Systems (San Diego, CA, USA), a company specializing in organ-specific high resolution positron emission tomography (PET) scanners, presented new clinical data using the PEM Flex scanner in breast cancer management at the Society of Nuclear Medicine's annual meeting, held in New Orleans, LA, USA, in June 2008. More...
The PEM Flex Solo II is a commercially available, U.S. Food and Drug- (FDA)-cleared scanner that utilizes PET technology for the breast application known as PEM.

Findings presented from an independent study of 136 patients comparing the accuracy of PEM and MRI in the pre-surgical planning of breast cancer patients indicated that PEM technology is more sensitive than MRI in detecting the smallest cancers. PEM demonstrated 91% sensitivity in-ductal carcinoma in situ (DCIS) compared to 83% with MRI and better sensitivity in cancers less than five mm in size. PEM also detected a 2-mm DCIS case shown to be negative on MRI.

"In our research, PEM accurately detected and characterized the smallest and most difficult to see cancers--specifically DCIS, which is often impossible to see with other imaging modalities,” said Kathy Schilling, M.D. and medical director of the Center for Breast Care (Boca Raton, FL, USA), who has been studying PEM for more than two years. "The ability to image and diagnose these early stage cancers provides the potential for cure and will significantly impact breast cancer management.”

Dr. Schilling has been using the PEM Flex scanner in her practice as a tool for evaluating additional and unsuspected disease in the breast and compares these findings with that of MRI. She is also a lead investigator in a 400 patient, multi-center clinical trial comparing PEM and MRI in breast cancer patients.

Naviscan PET Systems develops and markets compact, high-resolution PET scanners intended to provide organ-specific molecular imaging, guide radiologic and surgical procedures and advance new clinical therapies. The PEM Flex Solo II is currently installed and available in breast centers and imaging centers throughout the U.S. PEM Flex is also utilized in clinical research studies, funded in part by the U.S. National Institutes of Health (Bethesda, MD, USA). The company is the first company to obtain FDA clearance of a high-resolution PET scanner designed to image small body parts.


Related Links:
Naviscan PET Systems

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Patient Preoperative Skin Preparation
BD ChloraPrep
Fetal Monitor
BT-380
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Clinical LLM Performance Improves by >300% When Provided with High-Quality Real-World Evidence in New Precision Medicine Benchmark (Photo courtesy of Atropos Health)

New Benchmark Highlights Evidence Gaps in AI Responses to Clinical Questions

Many clinical decisions still rely on limited evidence, while most artificial intelligence benchmarks overlook the patient context that shapes real-world care. General large language models can also struggle... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.